Switzerland’s Roche has announced its acquisition of U.S. biopharma firm Poseida Therapeutics in a cash deal valued at up to $1.5 billion. Under the terms of the agreement, Poseida shareholders will receive $9 per share in cash, along with a non-tradeable contingent value right that could yield up to $4 per share if certain milestones are achieved, bringing the total potential value of the deal to approximately $1.5 billion. The acquisition is expected to close in the first quarter of 2025.
Kristin Yarema, president and CEO of Poseida, expressed enthusiasm about the merger, stating, “We have worked closely with Roche through our collaboration focused on hematologic malignancies, and we are excited to join Roche to work as colleagues on our pipeline and future programs.”
Poseida and its employees will integrate into Roche’s pharmaceuticals division as part of the acquisition. This move will enhance Roche’s capabilities in allogeneic cell therapy, particularly in CAR-T programs, which are already covered by their existing collaboration in treating hematologic malignancies. The acquisition will also expand Roche’s portfolio to include CAR-T programs for solid tumors and autoimmune diseases, as well as Poseida’s genetic engineering platform and related pre-clinical medicines.
About Author
